Larimar Therapeutics (LRMR) EV to CFO (2020 - 2025)
Larimar Therapeutics' (LRMR) quarterly EV to CFO came in at 2.4 in Q2 2025, up 85.8% on a YoY basis from 1.29 in Q2 2024, and down 420.64% quarter-over-quarter from 0.75 in Q1 2025.
Powered by 
Analysis
Larimar Therapeutics (LRMR) EV to CFO (2020 - 2025) Analysis & Trends
Larimar Therapeutics (LRMR) has reported EV to CFO for 6 consecutive years, with 2.4 the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, EV to CFO rose 85.8% year-over-year to 2.4; the trailing twelve-month figure through Jun 2025 stood at 0.5 (up 90.84% YoY), and the FY2025 full-year result was 1.59, down 76.99% from the prior year.
- EV to CFO slipped to 2.4 in Q2 2025 per LRMR's latest filing, from 0.75 in the prior quarter.
- Across five years, EV to CFO topped out at 9.11 in Q3 2022 and bottomed at 24.68 in Q1 2024.
- Historically, EV to CFO has averaged 6.87 across 5 years, with a median of 7.95 in 2021.
- The sharpest annual moves came in 2021 and 2022: EV to CFO tumbled 1222.7% in 2021, then surged 192.88% in 2022.
- Over 5 years, EV to CFO stood at 15.28 in 2021, then surged by 111.8% to 1.8 in 2022, then tumbled by 767.64% to 12.04 in 2023, then surged by 75.87% to 2.91 in 2024, then advanced by 17.41% to 2.4 in 2025.
- According to Business Quant data, EV to CFO over the past three periods registered 2.4, 0.75, and 2.91 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2.40 |
| Mar 31, 2025 | 0.75 |
| Dec 31, 2024 | -2.91 |
| Sep 30, 2024 | -8.73 |
| Jun 30, 2024 | -16.91 |
| Mar 31, 2024 | -24.68 |
| Dec 31, 2023 | -12.04 |
| Sep 30, 2023 | -8.46 |
| Jun 30, 2023 | -4.24 |
| Mar 31, 2023 | -11.19 |
| Dec 31, 2022 | 1.80 |
| Sep 30, 2022 | 9.11 |
| Jun 30, 2022 | 2.70 |
| Mar 31, 2022 | -1.21 |
| Dec 31, 2021 | -15.28 |
| Sep 30, 2021 | -9.81 |
| Jun 30, 2021 | -7.45 |
| Mar 31, 2021 | -12.77 |
| Dec 31, 2020 | -16.41 |
| Sep 30, 2020 | -11.64 |